Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes after reduced-intensity conditioning based HCT for dyskeratosis congenita

Akshay Sharma • 2 Feb 2021
TCT 2021
General Busulfan

Dyskeratosis congenita is a multisystem disorder caused by impaired telomere maintenance. In this interview, Akshay Sharma, MBBS, of St. Jude Children’s Research Hospital, Memphis, TN, outlines the outcomes of patients with dyskeratosis congenita treated with reduced-intensity conditioning based hematopoietic cell transplantation (HCT). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Akshay Sharma

1:45
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Akshay Sharma • 12 Dec 2022
1:44
Phase II study of MGTA-145 in combination with plerixafor for HSC mobilization in patients with SCD
Akshay Sharma • 12 Dec 2022
0:56
Treatment of severe SCD with OTQ923 CRISPR/Cas9 gene therapy
Akshay Sharma • 12 Dec 2022
2:43
A machine learning model to improve outcome prediction following allogeneic transplantation
Akshay Sharma • 12 Dec 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals